AbbVie Inc (ABBV)vs20/20 Biolabs, Inc. Common Stock (AIDX)
ABBV
AbbVie Inc
$205.03
-0.52%
HEALTHCARE · Cap: $365.43B
AIDX
20/20 Biolabs, Inc. Common Stock
$1.49
-1.97%
HEALTHCARE · Cap: $15.62M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 3071584% more annual revenue ($62.82B vs $2.05M). ABBV leads profitability with a 5.8% profit margin vs -182.8%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
AIDX
Avoid15
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-22.6%
Fair Value
$168.19
Current Price
$205.03
$36.84 premium
Intrinsic value data unavailable for AIDX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
No standout strengths identified
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
0.4% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -503.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : AIDX
AIDX has a balanced fundamental profile.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.8x leaves little room for execution misses.
Bear Case : AIDX
The primary concerns for AIDX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a value stock while AIDX is a turnaround play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.36 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 15/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
20/20 Biolabs, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
20/20 Biolabs, Inc. (ticker: AIDX) is a forward-thinking biotechnology company dedicated to advancing genomic research and diagnostics through innovative laboratory services. By focusing on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is at the forefront of molecular diagnostics. With a strong commitment to harnessing cutting-edge technologies, 20/20 Biolabs is well-positioned to lead the charge in personalized medicine as the demand for genomic data accelerates. The company’s strategic initiatives and robust market positioning signal a promising growth trajectory in the dynamic biotechnology sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?